Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells

Lignende værker

• Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
  af: LI, JING, et al.
  Udgivet: (2013)
• MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
  af: Wang, Qiming, et al.
  Udgivet: (2019)
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
  af: Cross, Darren A. E., et al.
  Udgivet: (2014)
• Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
  af: Ju Lixia, et al.
  Udgivet: (2013-02-01)
• Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
  af: Ju, Lixia, et al.
  Udgivet: (2013)